California-based MapLight Therapeutics (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on novel therapies for neuropsychiatric disorders, provided an update on the progress of its two ongoing Phase 2 studies.
The Phase 2 ZEPHYR trial evaluating ML-007C-MA, a muscarinic M1/M4 positive allosteric modulator, in adults with schizophrenia is enrolling ahead of schedule.
The double-blind, placebo-controlled study is designed to randomize approximately 300 hospitalized adult participants experiencing acute psychosis.
The Phase 2 IRIS trial of ML-004, a trace amine-associated receptor 1 (TAAR1) agonist, in autism spectrum disorder has completed enrollment, randomizing roughly 160 adolescent and adult participants in a double-blind, placebo-controlled design.
Management attributed the accelerated timelines to strong site activation and patient interest, enabling the company to narrow its previous guidance and now expect topline results from both trials in the third quarter of 2026.
The updates highlight momentum in MapLight's pipeline as it advances differentiated mechanism-based therapies targeting core symptoms in schizophrenia and autism spectrum disorder.